APVO · Aptevo Therapeutics Inc.
AI read · Bad for APVO
The AI's read
The cash can fund working capital and general company needs. More money depends on holders exercising the new warrants after stockholder approval. Those warrants could add 5 shares for every share issued in the current exercise, sharply shrinking each current owner's share of the company. That risk outweighs the immediate cash benefit.